Type 1 diabetes is a metabolic disorder syndrome characterized by hyperglycemia caused by absolute insulin deficiency.

The routines of currently available semi-automatic insulin delivery systems are still not convenient enough and require individualized insulin regimens to be developed. And it requires reference to the carbohydrate dose in the patient's diet.

In contrast, bionic pancreas devices are simpler and more efficient, requiring only an initialized dose setting based on body weight, with an algorithm that continuously and automatically adjusts the insulin dose according to the user's needs.

Recently, the New England Journal of Medicine (NEJM) published the results of a multicenter randomized trial that evaluated the Bionic Pancreas device (insulin infusion only, without glucagon).

Effectiveness and safety in adults with type 1 diabetes and children aged 6 years and older. Clinical trials have shown greater reductions in glycated hemoglobin (HbA1c) levels and longer time to glycemic target in patients using the bionic pancreas compared to standard therapy.

One of the principal investigators, Professor Dr. Nelly Mauras, a pediatric endocrinologist, and diabetologist from Mayo Clinic, one of the world's leading medical institutions, said, "Bionic pancreas technology is able to better manage blood glucose in patients of all ages compared to currently available insulin delivery devices.

This is a major leap forward in artificial pancreas technology and can reduce the investment in blood glucose management for both healthcare professionals and patients."